Tamarack Advisers, LP Exelixis, Inc. Transaction History
Tamarack Advisers, LP
- $2.12 Billion
- Q4 2023
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
467Shares Held
239MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$1.14 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$1.01 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$925 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$517 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$430 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...